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Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, 
splenomegaly, and elevated proinflammatory cytokine levels. The Janus kinase/signal transducer and 
activator of transcription (JAK/STAT) pathway is the central pathway implicated in the pathogenesis of 
MF.1,2 One of the other pathways dysregulated in MF includes the phosphatidylinositol-3-kinase 
(PI3K)/Akt pathway.3 Ruxolitinib, a first-in-class JAK1/2 inhibitor (JAKi), is approved in the US and EU 
for treatment of MF and polycythemia vera after an inadequate response or intolerance to hydroxyurea. 
Buparlisib, an oral pan-PI3K inhibitor, showed favorable tolerability/efficacy profile in patients with solid 
tumors.4 
 
Targeting multiple signaling pathways might have a synergistic therapeutic effect on the underlying 
pathogenesis of MF.5 For patients who do not respond to JAKi or those who lose their response, a rational 
combination of other targeted agents is a promising strategy.6,7 Preclinical data suggest that inhibition of 
the PI3K/mTOR pathway has beneficial effects in MF.8-10 HARMONY, a phase 1b, 2-arm, open-label, 
multicenter, dose-finding study, investigated the safety and efficacy of the oral combination of ruxolitinib 
and buparlisib in adult patients with intermediate/high-risk primary MF, post-polycythemia vera MF, or 
post-essential thrombocythemia MF (Online Supplementary Figure 1). The maximum tolerated dose 
(MTD)/recommended phase 2 dose (RP2D) was established at 15 mg twice daily (bid) for ruxolitinib and 
60 mg once daily (qd) for buparlisib. The dose-limiting toxicity (DLT) and adverse event (AE) profile of 
the combination was similar to the safety profile of the individual drugs and resulted in an overall 
moderate clinical benefit compared with ruxolitinib monotherapy. 
Patients without prior JAKi treatment (JAKi naïve) and with prior JAKi treatment including ruxolitinib 
(prior JAKi) were enrolled simultaneously into the 2 arms of the study. 
The study consisted of 2 periods, namely the treatment period (cycle 1 day 1 to cycle 7 day 1 [C7D1]) and 
treatment extension period (C7D1 to cycle 12 day 28 [C12D28]). The treatment period comprised 6 
cycles of 28 days per cycle. At the end of the treatment period, on C7D1, patients benefiting from the 
treatment as per the investigator’s discretion with no evidence of disease progression could enter the 
treatment extension period. Patients not meeting this criteria were discontinued from the study at the end 
of the treatment period. A follow-up visit was scheduled 30 days after the end-of-treatment visit (C7D1, 
C12D28, or premature discontinuation).  
The study comprised dose-escalation and expansion phases. In the dose-escalation phase, successive 
cohorts of minimum 3 patients received increasing doses of ruxolitinib (5 mg bid to 40 mg bid) and 
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buparlisib (40 mg qd to 100 mg qd) until the MTD/RP2D was reached. An additional 6 patients were 
enrolled to determine a dose level as the MTD/RP2D.  
 
The primary objective was to establish the MTD/RP2D of the combination of ruxolitinib and buparlisib in 
each arm as assessed by the incidence rate of DLTs. The key secondary objective was to evaluate safety. 
Further details of the eligibility criteria, methods, other secondary objectives, and the statistical analysis 
used for this study are provided in the Online Supplementary Material.  
  
Sixty-three patients (46% with primary MF, 31.7% with post-polycythemia vera  MF, and 22.2% with 
post-essential thrombocythemia MF) were enrolled in the study (JAKi naïve, n=33; prior JAKi, n=30). 
The baseline characteristics and patient disposition are summarized in Table 1. At baseline, prior JAKi 
patients had lower hemoglobin and platelet counts and a higher white blood cell count compared with 
JAKi-naïve patients. AEs (33.3%) were the primary reason for end of treatment. In the dose-escalation 
phase, dose levels included for the ruxolitinib bid/buparlisib qd combination were 10 mg/60 mg (dose 
level 1, n=15), 15 mg/60 mg (dose level 2, n=42), 15 mg/80 mg (dose level 3, n=3), and 20 mg/80 mg 
(dose level 4, n=3). The median duration of exposure to ruxolitinib at MTD was 79.5 weeks (12–167.6 
weeks) and 54.6 weeks (8–151.3 weeks) in the JAKi-naïve and prior JAKi arms, respectively, and to 
buparlisib was 79.4 weeks (2.4–167.4 weeks) and 54.5 weeks (7.1–151.1 weeks), respectively. The 
analysis set per dose level is presented in Online Supplementary Table 1. 
In the overall population, 5 patients (JAKi naïve, n=3; prior JAKi, n=2) experienced DLTs during the first 
28 days; thrombocytopenia (JAKi naïve, n=2; prior JAKi, n=1), anxiety (JAKi naïve, n=1; prior JAKi, 
n=0), and depression (JAKi naïve, n=0; prior JAKi, n=1). MTD/RP2D was established at ruxolitinib 
15 mg bid/buparlisib 60 mg qd (dose level 2) for both arms.11 The MTD/RP2D remained the same as 
confirmed by the results of the expansion cohort, based on the 56 patients in the dose-determining set 
(Table 2). 
All patients included in the safety set (n=63) experienced ≥1 AE (Online Supplementary Table 2). In the 
MTD population, anxiety, depression, dizziness, dyspnea, and stomatitis were the most common 
nonhematologic AEs. The most frequent all-grade hematologic AEs included thrombocytopenia (JAKi 
naïve, 63.6%; prior JAKi, 55.0%) and anemia (JAKi naïve, 50.0%; prior JAKi, 55.0%). Grade 3/4 
thrombocytopenia was higher with prior JAKi (35.0%) compared with JAKi naïve (22.7%). Pneumonia 
(JAKi naïve, 9.1%; prior JAKi, 15%) and pyrexia (JAKi naïve, 4.5%; prior JAKi, 10%) were the most 
common serious AEs in both arms. Progression to acute myeloid leukemia was also reported (JAKi naïve, 
4.5%; prior JAKi, 10%). 
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Primary AEs leading to study drug discontinuation in the MTD population included thrombocytopenia 
(n=3), anxiety (n=2), and depression (n=2) in the JAKi-naïve arm and progression to acute myeloid 
leukemia (n=2) in the prior JAKi arm. Dose reduction/interruptions in the JAKi-naïve arm and prior JAKi 
arm were due to thrombocytopenia (n=10; n=8, respectively) and anemia (n=2 in both arms). 
The frequency of infections, thrombocytopenia, and psychiatric disorders were similar or slightly higher 
in the prior JAKi arm compared with the JAKi-naïve arm (Table 3). Seven on-treatment deaths occurred, 
which were not related to the study treatment (Online Supplementary Table 3). 
At C7D1 and C12D28, proportion of MTD patients achieving ≥50% of reduction in spleen length was 12 
of 16 (75.0%) and 13 of 15 (86.7%), respectively, in the JAKi-naïve arm and 6 of 17 (35.3%) and 4 of 11 
(36.4%), respectively, in the prior JAKi arm. At C7D1, proportion of MTD patients in the expansion 
phase achieving ≥35% of reduction in spleen volume was 5 of 9 (55.6%) in the JAKi-naïve arm and 3 of 
7 (42.9%) in the prior JAKi arm (Online Supplementary Figure 2A and Online Supplementary Figure 
2B). Best response in spleen volume reduction in MTD patients is presented in Online Supplementary 
Figure 2C.  
There was remarkable improvement in global health status/quality of life, which was more prominent in 
the JAKi-naïve arm than the prior JAKi arm at both C7D1 and C12D28. Improvement in the 7-day 
Myelofibrosis Symptom Assessment Form (MFSAF) from baseline to week 24 in both the arms is shown 
in Online Supplementary Table 4. A modest effect was observed on allele burden in both the arms. 
Among MTD patients, improvement in bone marrow fibrosis (n=1 in each arm), stabilization 
(JAKi naïve, n=2; prior JAKi, n=4), and worsening by the end of treatment (JAKi naïve, n=1) were 
observed. Data for overall population are presented in Online Supplementary Table 5. Buparlisib did not 
impact the pharmacokinetics of ruxolitinib (Online Supplementary Table 6). 
 
To the best of our knowledge, HARMONY is the first study presenting safety and efficacy data on 
ruxolitinib and buparlisib combination in patients with MF. MTD for the combination was determined to 
be 15 mg bid for ruxolitinib and 60 mg qd for buparlisib in both JAKi-naïve and prior JAKi arms.11 
Individual MTDs were 25 mg bid for ruxolitinib and 100 mg qd for buparlisib.12,13 In our study, MTD for 
the combination constituted lower doses for both the drugs when compared with the single agents. 
Additionally, no unexpected DLTs were observed with the combination. Thrombocytopenia, anxiety, and 
depression were the DLTs observed with the combination in our study, which are consistent with the 
known profile of these 2 drugs.12,13 The combination was well tolerated with a manageable safety profile 
and provided clinically relevant efficacy. No new safety signals were observed.  
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Approximately, 40% of the patients had a spleen volume reduction of ≥35% with the combination in the 
expansion phase. With ruxolitinib alone, 41.9% of patients at week 24 in COMFORT-I and 28% of 
patients at week 48 in COMFORT-II achieved spleen volume reduction of ≥35%.14,15 In our study, the 
anticipated synergistic effect of the combination was not observed on spleen response. The combination 
demonstrated a modest effect in JAK allele burden in both the arms, and only a few patients had 
improvement or stabilization in bone marrow fibrosis. However, 2 factors have to be taken into account 
before interpreting this data; the small sample size and short duration of the study. 
 
Based on the modest, overall benefit-risk profile and efficacy, the ruxolitinib and buparlisib combination 
will not be progressed at this time. 
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Table 1. Baseline patient characteristics and patient disposition (full analysis set) 
Demographic Variable 
MTD Overall 
JAKi naïve 
N=22 
n (%) 
Prior JAKi 
N=20 
n (%) 
JAKi naïve  
N=33 
n (%) 
Prior JAKi  
N=30 
n (%) 
Total 
N=63 
n (%) 
Age, median (range), years 63.0 (37, 83) 
63.5 
(50, 79) 
64.0 
(37, 83) 
62.0 
(50, 79) 
63.0 
(37,83) 
≥65 years 9 (40.9) 10 (50.0) 14 (42.4) 13 (43.3) 27 (42.9) 
Male 15 (68.2) 15 (75.0) 20 (60.6) 20 (66.7) 40 (63.5) 
MF subtype 
PMF 
PPV MF 
PET MF 
9 (40.9) 
9 (40.9) 
4 (18.2) 
12 (60.0) 
5 (25.0) 
3 (15.0) 
12 (36.4) 
12 (36.4) 
9 (27.3) 
17 (56.7) 
8 (26.7) 
5 (16.7) 
29 (46.0) 
20 (31.7) 
14 (22.2) 
IPSS at study entry  
Intermediate 1 
Intermediate 2 
High risk 
6 (27.3) 
6 (27.3) 
10 (45.5) 
1 (5.0) 
6 (30.0) 
13 (65.0) 
9 (27.3) 
7 (21.2) 
17 (51.5) 
3 (10.0) 
8 (26.7) 
19 (63.3) 
12 (19.0) 
15 (23.8) 
36 (57.1) 
Outcome of previous treatment with JAKi 
Nonresponder 
Suboptimal responder 
(<25%) 
Suboptimal responder 
(25%–49%) 
Prior spleen responder with 
subsequent progression 
NA 
0 
0 
0 
0 
22 (100.0) 
5 (25.0) 
2 (10.0) 
3 (15.0) 
10 (50.0) 
0 
 
0 
0 
0 
0 
33 (100.0) 
8 (26.7) 
3 (10.0) 
4 (13.3) 
15 (50.0) 
0 
8 (12.7) 
3 (4.8) 
4 (6.3) 
15 (23.8) 
33 (52.4) 
Median time since diagnosis, 
months 
6.57 
(0.46, 209.71) 
43.55 
(9.63, 304.79) 
7.852 
(0.46, 209.71) 
54.85 
(9.63, 304.79) 
31.70 
(0.46, 304.79) 
JAK2 V617F-positive 15 (68.2) 13 (65.0) 24 (72.7) 20 (66.7) 44 (69.8) 
JAK2 V617F-positive allele 
burden, median (range) 
73.49  
(2.5, 95) 47.81 (2.5, 95) 65.24 (2.5, 95) 47.81 (2.5, 95) 52.02 (2.5, 95) 
Hemoglobin, g/L, median 
(range) 
113.5  
(85, 141) 
94  
(71, 156) 
110  
(81, 144) 
96.5  
(71, 157) 
106  
(71, 157) 
Platelet count, × 109/L, 
median (range) 
237  
(113, 627) 
169  
(81, 939) 
231  
(83, 627) 
159  
(80, 939) 
209  
(80, 939) 
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WBC, × 109/L, median 
(range) 16.5 (2.6, 90) 21.9 (3.1, 86) 17 (2.6, 199.5) 14.6 (3.1, 86) 
15.9 (2.6, 
199.5) 
Blast percentage, median 
(range) 2 (0, 9) 2 (0, 6) 1 (0, 9) 2 (0, 6) 2 (0, 9) 
Reason for disposition 
End of treatment 22 (100.0%) 20 (100.0%) 33 (100.0%) 30 (100.0%) 63 (100.0%) 
Primary reasons for end of treatment 
Adverse event(s) 10 (45.5%) 6 (30.0%) 12 (36.4%) 9 (30.0%) 21 (33.3%) 
Subject withdrew consent 2 (9.1%) 0 3 (9.1%) 1 (3.3%) 4 (6.3%) 
Administrative problems 4 (18.2%) 3 (15.0%) 6 (18.2%) 4 (13.3%) 10 (15.9%) 
Death 1 (4.5%) 1 (5.0%) 2 (6.1%) 1 (3.3%) 3 (4.8%) 
Disease progression 2 (9.1%) 6 (30.0%) 3 (9.1%) 8 (26.7%) 11 (17.5%) 
Treatment duration 
completed 2 (9.1%) 2 (10.0%) 4 (12.1%) 5 (16.7%) 9 (14.3%) 
Lack of efficacy 1 (4.5%) 2 (10.0%) 3 (9.1%) 2 (6.7%) 5 (7.9%) 
Primary reasons for study evaluation completion 
Adverse event(s) 5 (22.7%) 4 (20.0%) 7 (21.2%) 5 (16.7%) 12 (19.0%) 
Subject withdrew consent 2 (9.1%) 0 2 (6.1%) 1 (3.3%) 3 (4.8%) 
Administrative problems 4 (18.2%) 1 (5.0%) 5 (15.2%) 1 (3.3%) 6 (9.5%) 
Death 2 (9.1%) 4 (20.0%) 3 (9.1%) 4 (13.3%) 7 (11.1%) 
Disease progression 2 (9.1%) 2 (10.0%) 3 (9.1%) 3 (10.0%) 6 (9.5%) 
Follow-up phase completed 
as per protocol 7 (31.8%) 8 (40.0%) 11 (33.3%) 15 (50.0%) 26 (41.3%) 
Lack of efficacy 0 1 (5.0%) 2 (6.1%) 1 (3.3%) 3 (4.8%) 
IPSS, International Prognostic Scoring System; JAKi=janus kinase inhibitor; MF=myelofibrosis; MTD=maximum tolerated 
dose; PET MF=post-essential thrombocythemia myelofibrosis; PMF=primary myelofibrosis; PPV MF=post-polycythemia vera 
myelofibrosis; WBC=white blood count. 
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Table 2. Dose-limiting toxicities occurring during cycle 1 (dose-determining set) 
  
Thrombocytopenia 
n (%) 
Anxiety 
n (%) 
Depression 
n (%) 
JAKi naïve 
Dose level 1 (N=8) 1 (12.5) 0 (0.0) 0 (0.0) 
Dose level 2* (N=19) 1 (5.3) 1 (5.3) 0 (0.0) 
Total (N=27) 2 (7.4) 1 (3.7) 0 (0.0) 
JAKi prior 
Dose level 1 (N=4) 0 (0.0) 0 (0.0) 0 (0.0) 
Dose level 2* (N=19) 0 (0.0) 0 (0.0) 0 (0.0) 
Dose level 3 (N=3) 0 (0.0) 0 (0.0) 0 (0.0) 
Dose level 4 (N=3) 1 (33.3) 0 (0.0) 1 (33.3) 
Total (N=29) 1 (3.4) 0 (0.0) 1 (3.4) 
*MTD. Dose level 1, ruxolitinib 10 mg bid/buparlisib 60 mg qd; dose level 2, ruxolitinib 15 mg bid/buparlisib 60 mg qd; dose 
level 3, ruxolitinib 15 mg bid/buparlisib 80 mg qd; dose level 4, ruxolitinib 20 mg bid/buparlisib 80 mg qd. bid=twice weekly; 
JAKi=Janus kinase inhibitor; MTD=maximum tolerated dose; qd=once daily. 
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Table 3. Adverse events of special interest (≥30% in either arm) for ruxolitinib and buparlisib, regardless of 
study drug relationship by arm (safety set) 
 Specific safety events 
All JAKi-naïve patients 
N=33 
n (%) 
All prior JAKi patients 
N=30 
n (%) 
Any specific safety event categories for ruxolitinib 
Total 32 (97.0) 29 (96.7) 
Infections excluding tuberculosis 23 (69.7) 21 (70.0) 
Thrombocytopenia 19 (57.6) 21 (70.0) 
Anemia 16 (48.5) 14 (46.7) 
Hemorrhage 15 (45.5) 14 (46.7) 
Any specific safety event categories for buparlisib 
Total 33 (100) 30 (100) 
Thrombocytopenia, anemia, lymphopenia, neutropenia 24 (72.7) 24 (80.0) 
Nausea, vomiting diarrhea 20 (60.6) 22 (73.3) 
Respiratory tract infections 15 (45.5) 17 (56.7) 
Psychiatric disorders 15 (45.5) 16 (53.3) 
Asthenia, fatigue 8 (24.2) 18 (60.0) 
Lipase increase 11 (33.3) 15 (50.0) 
Hyperglycemia 12 (36.4) 12 (40.0) 
Cardiovascular events 5 (15.2) 9 (30.0) 
JAKi=janus kinase inhibitor. 
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Eligibility criteria 
Patients were eligible to enroll in the study if they met all the following criteria at screening: 
intermediate or high-risk prognostic criteria, palpable splenomegaly ≥ 5 cm below the costal 
margin, active symptoms of MF as demonstrated by MF Screening Symptom Form, platelet 
counts ≥ 75 x 109/L not reached with the aid of transfusions and an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0, 1, or 2. Patients were excluded if they had 
received previous treatment with PI3K inhibitors, AKT inhibitors, and JAKi (including 
ruxolitinib) that resulted in clinically significant toxicities at the discretion of the investigator. 
Patients who have had splenic irradiation within 12 months prior to screening, patients with 
specific mood disorders, active infection, inadequate liver or renal function, history of bleeding 
diathesis, and patients who were ready for a stem cell transplantation at the time of the screening 
were excluded. 
 
Methods 
As per protocol, disease progression was defined as a spleen length increase of >40% from the 
baseline as assessed by palpation. The end of study had occurred after all patients in the study 
had completed their last assessment as per protocol. The dose escalation was guided by a 
Bayesian logistic regression model with overdose control, dependent on dose-limiting toxicities 
(DLTs) in cycle 1 and other safety findings. A DLT was defined as an adverse event (AE) or 
abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current 
illness, or concomitant medications that occurs within the first 28 days.  
The MTD/RP2D was defined as the dose level most closely associated with a posterior DLT 
probability of between 16% and 35% that does not also have a greater than 25% of probability of 
excessive toxicity (determined independently for both the arms). Once the MTD level was 
reached, patients entered in the expansion phase. In the expansion phase, an additional 10 
patients in each arm, in addition to those treated at the MTD and/or RP2D during dose 
escalation, were treated at the respective MTD and/or RP2D for their respective arm. In total, 
approximately 62 patients were planned to be enrolled in dose determining set. Unless specified 
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otherwise, safety and efficacy data presented were by dose level, by arm, and for overall and/or 
MTD population. 
 
Other secondary objectives 
The other secondary objective was to characterize the pharmacokinetics of ruxolitinib alone and 
in combination with buparlisib, as well as the pharmacokinetics of buparlisib at varying doses 
when given in combination in patients with MF. The exploratory objectives included estimates of 
efficacy (spleen length assessed by palpations and volumetric spleen size by magnetic resonance 
imaging [MRI]/computed tomography [CT]), changes in symptoms of MF, patient-reported 
outcomes, changes in transfusion dependence, potential predictive biomarkers of response to the 
combination, changes in markers of disease burden and symptoms, and pharmacokinetic-
pharmacodynamics (PK-PD) relationship of this combination. 
 
Statistical analysis 
No formal statistical power calculations were performed to determine the sample size of this 
study. The full analysis set included all patients who received at least one dose of ruxolitinib or 
buparlisib. The safety set included all patients who received at least one dose of ruxolitinib or 
buparlisib, and had at least one valid post-baseline safety assessment. The dose-determining set 
consisted of all patients from the safety set who either met a minimum exposure criterion 
(received ≥80% of twice daily doses of ruxolitinib and ≥80% of planned daily doses of 
buparlisib) and had sufficient safety evaluations during cycle 1 or experienced a DLT during 
cycle 1. The pharmacokinetic (PK) analysis set consisted of all patients who had at least one 
blood sample providing evaluable PK data. The study was not adequately powered to assess the 
specific biomarker-related hypotheses; thus, statistical analyses of these data should be 
considered to be exploratory in nature. 
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Supplementary Figure 1. Study design and dose levels
 
Supplementary Figure 2. (A) Box plot for spleen length in MTD patients (Ruxolitinib 15 
mg bid, Buparlisib 60 mg qd) 
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Supplementary Figure 2. (B) Box plot for spleen volume in MTD patients (Ruxolitinib 15 
mg bid, Buparlisib 60 mg qd) 
Supplementary Figure 2. (C) Best response in spleen volume (cm3) by arm (Expansion 
patients in Full analysis set) 
 
 
 
   
 JAK naïve Prior JAK 
Decrease in best percentage change from baseline 90.9% (10)      81.8% (9) 
Increase in best percentage change from baseline 0.0% (0) 9.1% (1) 
No change from baseline 0.0% (0) 0.0% (0) 
Missing post-baseline assessments 9.1% (1) 9.1% (1) 
N is the number of patients in Full Analysis Set. Percentages above use N as denominator. 
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Supplementary Table 1. Analysis set 
 
Dose level 1 
N=15 
n (%) 
Dose level 2* 
N=42 
n (%) 
Dose level 3 
N=3 
n (%) 
Dose level 4 
N=3 
n (%) 
All patients 
N=63 
n (%) 
Full analysis set 15 (100) 42 (100) 3 (100) 3 (100) 63 (100) 
JAKi naïve 11 (73·3) 22 (52·4) 
  
33 (52·4) 
Prior JAKi 4 (26·7) 20 (47·6) 3 (100) 3 (100) 30 (47·6)  
Safety set 15 (100) 42 (100) 3 (100) 3 (100) 63 (100) 
JAKi naïve 11 (73·3) 22 (52·4) 
  
33 (52·4) 
Prior JAKi 4 (26·7) 20 (47·6) 3 (100) 3 (100) 30 (47·6)  
Dose-determining 
set 
12 (80.0) 38 (90·5) 3 (100) 3 (100) 56 (88·9) 
JAKi naïve 8 (53·3) 19 (45·2) 
  
27 (42·9) 
Prior JAKi 4 (26·7) 19 (45·2) 3 (100) 3 (100) 29 (46·0)  
Pharmacokinetic 
analysis set 
15 (100) 42 (100) 3 (100) 3 (100) 63 (100) 
JAKi naïve 11 (73·3) 22 (52·4) 
  
33 (52·4) 
Prior JAKi 4 (26·7) 20 (47·6) 3 (100) 3 (100) 30 (47·6) 
*Maximum tolerated dose (MTD). Dose level 1, ruxolitinib 10 mg bid/buparlisib 60 mg qd; dose level 2, ruxolitinib 
15 mg bid/buparlisib 60 mg qd; dose level 3, ruxolitinib 15 mg bid/buparlisib 80 mg qd; dose level 4, ruxolitinib 20 
mg bid/buparlisib 80 mg qd. JAKi=Janus kinase inhibitor. 
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Supplementary Table 2. Adverse events (≥10% cut off for all grades at MTD in the 
respective arm), regardless of study drug relationship per dose level and arm (safety set) 
(A) JAKi naïve
 
Dose level 1 
N=11 
n (%) 
Dose level 2* 
N=22 
n (%) 
 
All grades 
n (%) 
Grade 3 or 4 
n (%) 
All grades 
n (%) 
Grade 3 or 4 
n (%) 
Total 11 (100) 9 (81.8) 22 (100) 16 (72.7) 
Thrombocytopenia 3 (27.3) 2 (18.2) 14 (63.6) 5 (22.7) 
Anemia 5 (45·5) 5 (45·5) 11 (50.0) 5 (22.7) 
Anxiety 2 (18.2) 1 (9.1) 6 (27.3) 3 (13.6) 
Diarrhea 0 (0.0) 0 (0.0) 5 (22.7) 0 (0.0) 
Dizziness 1 (9.1) 0 (0.0) 5 (22.7) 0 (0.0) 
Asthenia 0 (0.0) 0 (0.0) 4 (18.2) 1 (4.5) 
Decreased appetite 0 (0.0) 0 (0.0) 4 (18.2) 0 (0.0) 
Depression 0 (0.0) 0 (0.0) 4 (18.2) 1 (4.5) 
Dyspnea 1 (9.1) 1 (9.1) 4 (18.2) 1 (4.5) 
Hematoma 1 (9.1) 0 (0.0) 4 (18.2) 0 (0.0) 
Abdominal pain 1 (9.1) 0 (0.0) 3 (13.6) 0 (0.0) 
Upper Abdominal pain 1 (9.1) 0 (0.0) 3 (13.6) 0 (0.0) 
Epistaxis 2 (18.2) 0 (0.0) 3 (13.6) 1 (4.5) 
Fatigue 1 (9.1) 0 (0.0) 3 (13.6) 0 (0.0) 
Nausea 1 (9.1) 0 (0.0) 3 (13.6) 0 (0.0) 
Night sweats 0 (0.0) 0 (0.0) 3 (13.6) 0 (0.0) 
Decreased platelet count 0 (0.0) 0 (0.0) 3 (13.6) 1 (4.5) 
Pneumonia 1 (9.1) 0 (0.0) 3 (13.6) 2 (9.1) 
Pruritus 1 (9.1) 0 (0.0) 3 (13.6) 0 (0.0) 
Stomatitis 1 (9.1) 0 (0.0) 3 (13.6) 1 (4.5) 
Urinary tract infection 3 (27.3) 0 (0.0) 3 (13.6) 0 (0.0) 
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(B) Prior JAKi 
   
Dose level 1 
N=4 
n (%) 
Dose level 2* 
N=20 
n (%) 
Dose level 3 
N=3 
n (%) 
Dose level 4 
N=3 
n (%) 
 
All 
grades 
n (%) 
Grade 3 
or 4 
n (%) 
All 
grades 
n (%) 
Grade 3 
or 4 
n (%) 
All 
grades 
n (%) 
Grade 3 
or 4 
n (%) 
All 
grades 
n (%) 
Grade 3 
or 4 
n (%) 
Total 4 (100) 3 (75·0) 20 (100) 16 (80.0) 3 (100) 3 (100) 3 (100) 3 (100) 
Anemia 1 (25.0) 0 (0.0) 11 (55·0) 8 (40.0) 1 (33.3) 1 (33.3) 
1 
(33.3) 1 (33.3) 
Thrombocytopenia 4 (100) 3 (75·0) 11 (55·0) 7 (35·0) 3 (100) 1 (33.3) 
1 
(33.3) 1 (33.3) 
Pyrexia 0 (0.0) 0 (0.0) 10 (50.0) 2 (10.0) 1 (33.3) 1 (33.3) 1 (33.3) 1 (33.3) 
Abdominal pain 0 (0.0) 0 (0.0) 8 (40.0) 1 (5·0) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 
Diarrhea 2 (50.0) 0 (0.0) 8 (40.0) 1 (5·0) 2 (66.7) 0 (0.0) 1 (33.3) 1 (33.3) 
Cough 0 (0.0) 0 (0.0) 8 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Peripheral edema 0 (0.0) 0 (0.0) 7 (35·0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0) 
Dyspnea 1 (25.0) 0 (0.0) 6 (30.0) 1 (5·0) 0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0) 
Fatigue 1 (25.0) 0 (0.0) 6 (30.0) 0 (0.0) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 
Asthenia 3 (75·0) 0 (0.0) 5 (25.0) 2 (10.0) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Upper respiratory 
tract infection 1 (25.0) 0 (0.0) 5 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Decreased appetite 1 (25.0) 0 (0.0) 4 (20.0) 1 (5·0) 2 (66.7) 1 (33.3) 2 (66.7) 0 (0.0) 
Constipation 0 (0.0) 0 (0.0) 4 (20.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Epistaxis 1 (25.0) 0 (0.0) 4 (20.0) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Pneumonia 0 (0.0) 0 (0.0) 3 (15.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Back pain 0 (0.0) 0 (0.0) 3 (15.0) 1 (5·0) 0 (0.0) 0 (0.0) 1 (33.3) 0 (0.0) 
Blood creatinine 
increased 0 (0.0) 0 (0.0) 3 (15.0) 1 (5·0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Hyperglycemia 0 (0.0) 0 (0.0) 3 (15.0) 1 (5·0) 0 (0.0) 0 (0.0) 1 (33.3) 1 (33.3) 
Hyperuricemia 1 (25.0) 0 (0.0) 3 (15.0) 1 (5·0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Pruritus 1 (25.0) 0 (0.0) 3 (15.0) 1 (5·0) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 
Dizziness 0 (0.0) 0 (0.0) 3 (15.0) 0 (0.0) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 
Oropharyngeal pain 1 (25.0) 0 (0.0) 3 (15.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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Respiratory tract 
infection 0 (0.0) 0 (0.0) 3 (15.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Vomiting 0 (0.0) 0 (0.0) 3 (15.0) 0 (0.0) 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 
Acute myeloid 
leukaemia 0 (0.0) 0 (0.0) 2 (10.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Multiple organ 
dysfunction 
syndrome 
0 (0.0) 0 (0.0) 
2 (10.0) 2 (10.0) 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Platelet count 
decreased 0 (0.0) 0 (0.0) 
2 (10.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Generalised oedema 0 (0.0) 0 (0.0) 2 (10.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Hyperkalaemia 0 (0.0) 0 (0.0) 2 (10.0) 1 (5.0) 0 (0.0) 0 (0.0) 1 (33.3) 
0 (0.0) 
Hypocalcaemia               1 (25.0) 0 (0.0) 2 (10.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Nausea                      1 (25.0) 0 (0.0) 2 (10.0) 1 (5.0) 1 (33.3) 0 (0.0) 2 (66.7) 
0 (0.0) 
Renal impairment 0 (0.0) 0 (0.0) 2 (10.0) 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Abdominal pain 
upper 1 (25.0) 
0 (0.0) 2 (10.0) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Alanine 
aminotransferase 
increased 
0 (0.0) 0 (0.0) 
2 (10.0) 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Aspartate 
aminotransferase 
increased 
1 (25.0) 0 (0.0) 
2 (10.0) 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Blood glucose 
increased  0 (0.0) 0 (0.0) 
2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Bone pain 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Dehydration  0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Depressed mood 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0) 
Early satiety 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Fluid overload 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Hematoma  0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Headache 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (33.3) 
0 (0.0) 
Hepatomegaly 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 1 (33.3) 0 (0.0)  0 (0.0) 
Insomnia 1 (25.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 2(66.7) 0 (0.0) 
Lethargy 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Localized edema 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Muscle spasm 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (33.3) 
0 (0.0) 
Night sweats 3 (75.0) 0 (0.0) 2 (10.0) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 
Petechiae  1 (25.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Pharyngitis 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Rash 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Viral upper 
respiratory tract 
infection  
0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 
1 (33.3) 
0 (0.0) 0 (0.0) 0 (0.0) 
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Weight decreased 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Weight increased 0 (0.0) 0 (0.0) 2 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
*MTD. Dose level 1, ruxolitinib 10 mg bid/buparlisib 60 mg qd; dose level 2, ruxolitinib 15 mg bid/buparlisib 60 
mg qd; dose level 3, ruxolitinib 15 mg bid/buparlisib 80 mg qd; dose level 4, ruxolitinib 20 mg bid/buparlisib 80 mg 
qd. JAKi=Janus kinase inhibitor; MTD=maximum tolerated dose; NR=not reported. 
 
 Supplementary Table 3. On-treatment deaths (safety set) 
 
JAKi-naïve Prior JAKia 
dose level 2* 
N=20 
n (%) 
All patients 
N=63 
n (%) 
Dose level 1 
N=11 
n (%) 
Dose level 2* 
N=22 
n (%) 
Total 1 (9.1) 2 (9.1) 4 (20.0) 7 (11·1) 
Acute myeloid leukemia 0 (0.0) 0 (0.0) 1 (5.0) 1 (1·6) 
Myeloid leukemia 0 (0.0) 0 (0.0) 1 (5.0) 1 (1·6) 
Leukemia 0 (0.0) 1 (4.5) 0 (0.0) 1 (1·6) 
Intracranial hemorrhage 0 (0.0) 0 (0.0) 1 (5·0) 1 (1·6) 
Congestive cardiac failure 0 (0.0) 1 (4.5) 0 (0.0) 1 (1·6) 
Duodenal ulcer 
hemorrhage 1 (9.1) 0 (0.0) 0 (0.0) 1 (1·6) 
Multiple organ dysfunction 
syndrome 0 (0.0) 0 (0.0) 1 (5·0) 1 (1·6) 
aNo deaths were reported in prior JAKi dose level 1, 3, 4 cohorts. *MTD. Dose level 1, ruxolitinib 10 mg 
bid/buparlisib 60 mg qd; dose level 2, ruxolitinib 15 mg bid/buparlisib 60 mg qd; dose level 3, ruxolitinib 15 mg 
bid/buparlisib 80 mg qd; dose level 4, ruxolitinib 20 mg bid/buparlisib 80 mg qd. JAKi=Janus kinase inhibitor; 
MTD=maximum tolerated dose. 
 
Supplementary Table 4. Proportion of patients achieving at least 50% reduction from 
baseline in total symptom scores of seven day MFSAF (Full analysis set) 
 MTD in JAKi-naïve arm (N=22) MTD in prior JAK arm (N=20) 
n at Week 24 17 17 
Number of patients achieving 
≥50% reduction in TSS at Week 
24, n (%) 
12 (70.6) 12 (70.6) 
95% CI of the response rate (44.0, 89.7) (44.0, 89.7) 
N only included patients that had a valid baseline assessment. N at Week 24 include patients that had Daily Total 
Scores at Week 24. 
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Supplementary Table 5. Shift table for bone marrow fibrosis grade by arm in the overall 
population (Full analysis set) 
Time 
Post-
baseline 
fibrosis 
grading 
JAK naïve 
N=33 
Baseline fibrosis grade, n (%) 
Prior JAKi 
N=30 
Baseline fibrosis grade, n (%) 
  0 1 2 3 Missing 0 1 2 3 
Missin
g 
Cycle 
7 day 1 
0 0 (0.0) 2 (6·1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3·3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 1 0 (0.0) 0 (0.0) 0 (0.0) 2 (6·1) 0 (0.0) 0 (0.0) 1 (3·3) 0 (0.0) 0 (0.0) 0 (0.0) 
 2 1 (3·0) 0 (0.0) 6 (18.2) 1 (3·0) 0 (0.0) 0 (0.0) 1 (3·3) 1 (3·3) 2 (6·7) 0 (0.0) 
 3 0 (0.0) 1 (3·0) 1 (3·0) 5 (15·2) 1 (3·0) 0 (0.0) 0 (0.0) 0 (0.0) 
10 
(33.3) 0 (0.0) 
 Missing 1 (3·0) 1 (3·0) 5 (15·2) 
4 
(12·1) 2 (6·1) 0 (0.0) 2 (6·7) 
4 
(13·3) 
6 
(20.0) 2 (6·7) 
            
Week 
96 
0 0 (0.0) 0 (0.0) 0 (0.0) 1 (3·0) 0 (0.0) 0 (0.0) 1 (3·3) 0 (0.0) 0 (0.0) 0 (0.0) 
 1 0 (0.0) 1 (3·0) 0 (0.0) 0 (0.0) 1 (3·0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 2 1 (3·0) 0 (0.0) 2 (6·1) 0 (0.0) 0 (0.0) 1 (3·3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3·3) 
 3 0 (0.0) 0 (0.0) 1 (3·0) 2 (6·1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (16·7) 0 (0.0) 
 Missing 1 (3·0) 3 (9.1) 9 (27.3) 
9 
(27.3) 2 (6·1) 0 (0.0) 
3 
(10.0) 
5 
(16·7) 
13 
(43·3) 1 (3·3) 
            
EOT 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 1 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 2 0 (0.0) 1 (3·0) 0 (0.0) 2 (6·1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3·3) 0 (0.0) 
 3 0 (0.0) 0 (0.0) 1 (3·0) 2 (6·1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (16·7) 0 (0.0) 
 Missing 2 (6·1) 3 (9.1) 11 (33.3) 
8 
(24·2) 3 (9.1) 1 (3·3) 
4 
(13·3) 
5 
(16·7) 
12 
(40.0) 2 (6·7) 
In the above figure, the green color indicates improvement; the orange color indicates stabilization, and the red color 
indicates worsening of bone marrow fibrosis. EOT=end of treatment; JAKi=Janus kinase inhibitor. 
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Supplementary Table 6. Summary of (A) ruxolitinib and (B) buparlisib pharmacokinetics 
A) Ruxolitinib pharmacokinetics 
PK 
parameter   
Dose level 1 
N=15 
Dose level 2* 
N=42 
Dose level 3 
N=3 
Dose level 4 
N=3 
AUClast 
(h*ng/mL)  
N 12 24 3 2 
Mean (SD) 435 (165) 564 (195) 550 (112) 1040 (55.3) 
Median 
(range) 
399 
(218, 797) 
510 
(264, 950) 
507 
(466, 677) 
1040 
(1000, 1080) 
Cmax 
(ng/mL)  
N 12 24 3 2 
Mean (SD) 136 (37.1) 189 (51.2) 231 (49.7) 383 (158) 
Median 
(range) 139 (77.3, 189) 178 (97.2, 293) 205 (199, 288) 383 (271, 494) 
Tmax (h)  
N 12 24 3 2 
Median 
(range) 1.00 (0, 1.50) 1.00 (0.417, 2.05) 0.500 (0.500, 0.517) 1.50 (1.50, 1.50) 
 
B) Buparlisib pharmacokinetics 
PK 
parameter 
 Dose level 1 
N=15 
Dose level 2* 
N=42 
Dose level 3 
N=3 
Dose level 4 
N=3 
AUClast 
(h*ng/mL)  
N 12 19 3 3 
Mean (SD) 3630 (1270) 3100 (1420) 5660 (1440) 4630 (738) 
Median 
(range) 3530 (2190, 6600) 3010 (563, 5670) 
4900 (4760, 
7320) 
4650 (3890, 
5360) 
Cmax 
(ng/mL)  
N 12 19 3 3 
Mean (SD) 444 (160) 414 (208) 564 (185) 579 (319) 
Median 
(range) 
416 
(241, 724) 360 (113, 870) 485 (432, 776) 488 (315, 934) 
Tmax (h)  
N 12 19 3 3 
Median 
(range) 1.73 (0.50, 2.05) 1.00 (0.50, 24.0) 1.50 (1.00, 1.98) 2.00 (1.00, 4.15) 
Maximum tolerated dose (MTD). Dose level 1, ruxolitinib 10 mg bid/buparlisib 60 mg qd; dose level 2, ruxolitinib 
15 mg bid/buparlisib 60 mg qd; dose level 3, ruxolitinib 15 mg bid/buparlisib 80 mg qd; dose level 4, ruxolitinib 20 
mg bid/buparlisib 80 mg qd. 
